FINWIRES · TerminalLIVE
FINWIRES

Update: CAR Group Fiscal Year 2026 Adjusted EPS, Revenue Up; Shares Gain 10%

By

(Updates with the stock movement in the headline and last paragraph.)

CAR Group (ASX:CAR) logged AU$1.076 in adjusted EPS for fiscal year 2026, compared with AU$0.998 a year ago, a Monday filing showed.

Analysts polled by FactSet expected about AU$1.071.

For the 12 months ended June 30, revenue was AU$1.25 billion versus AU$1.18 billion previously, the Australia-listed automotive marketplace operator added. Analysts surveyed by FactSet expected AU$1.27 billion.

The company's board declared a final dividend of AU$0.435 per share, up from AU$0.415 a year earlier, payable Oct. 12 to shareholders of record as of Sept. 14.

CAR Group guided for fiscal 2027 constant-currency revenue growth of 11% to 14% and adjusted net profit after tax growth of 9% to 12%.

The company's shares advanced 10% in recent Monday trade.

Related Articles

Asia

Aspial Lifestyle's H1 Attributable Profit Surges 88%

Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.

SGX:5UF
Asia

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.

HKG:1177
Asia

Lygend Resources Gets CSRC Nod for China Listed-Share IPO

Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.

HKG:2245